Key Takeaways:
- Viking Therapeutics faces increased net losses due to significant research and development expenses.
- The company's stock holds substantial upside potential based on analysts' price targets.
- Brokerage firms maintain an "Outperform" recommendation for VKTX.
Viking Therapeutics: Q1 Financial Insights
Viking Therapeutics (VKTX, Financial) has reported a first-quarter net loss greater than what analysts had predicted, primarily due to elevated research and development expenditures. The company disclosed a per-share loss of $0.41, which is significantly higher than the forecasted $0.31. Notably, no revenue was recorded for the quarter. A notable increase in research expenses, rising to $41.4 million from the previous year's $24.1 million, has negatively impacted the company's share value.
Wall Street Analysts' Forecast
Wall Street analysts have set one-year price targets for Viking Therapeutics Inc (VKTX, Financial). The average target price stands at $93.13, with estimates ranging between a high of $125.00 and a low of $30.00. This average target suggests a potential upside of 261.26% from the current stock price of $25.78. For more detailed estimate data, visit the Viking Therapeutics Inc (VKTX) Forecast page.
The consensus recommendation from 18 brokerage firms pegs Viking Therapeutics Inc's (VKTX, Financial) average rating at 1.7, indicating an "Outperform" status. This scale ranges from 1, representing a Strong Buy, to 5, indicating a Sell recommendation.
